《美股業績》連鎖藥房CVS(CVS.US)季績勝預期 料今年店內新冠疫苗接種大減
美國連鎖藥房及醫健保險集團CVS Health(CVS.US)公佈去年第四季業績。季度股東應佔純利12.96億美元,按年升32.9%。每股季度攤薄純利98美仙,經調整後爲1.98美元,高於市場預期的1.93美元,季度派息每股50美仙。季度收益766.04億美元,按年升10.1%,高於市場預期的756.7億美元。
公司預期今年分店接種新冠疫苗數字按年跌七至八成,店內新冠檢測按年減四至五成,預期非處方新冠檢測銷售全年溫和增長,今年盈利將主要由醫健保險及員工藥物福利管理業務。公司亦指,上季接種第三劑新冠疫苗推動店鋪銷售增長13%,業績展望未包括接種第四劑疫苗的情況。公司藥房上季接種逾2,000萬劑新冠疫苗,去年第三季爲約1,100萬劑。期內進行800萬次新冠檢測,與去年第三季相若。
CVS股價昨日(9日)跌5.5%報104.79美元,市場對公司沒有上調今年盈利預測感到失望。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.